EBOLA BREAKTHROUGH? As WHO Sets To Delibrate Experimental Drug For Ebola

A panel of World Health Organization ethicists will discuss whether to
use experimental drugs in the West African Ebola outbreak that has consume a total of 932 people since March.
Two American patients affected with the deadly disease have received an experimental drug of EBOLA called
ZMapp made by Mapp Pharmaceuticals, a 9-person company in San Diego.
Why We Don’t Have an Ebola Vaccine Yet Ebola-Stricken Doc Gives
'Experimental Serum' to Coworker
American Nurse With Ebola Back in
US, Making 'Slow Improvement'
The drug -- made of monoclonal
antibodies derived from plants -- had been shown to work in monkeys
within two days of infection, but it
had never been tested in humans
before. The patients, Dr. Kent Brantly
and missionary Nancy Writebol, have since been flown from Liberia to Emory University Hospital in Atlanta, where they are reportedly improving.
“We are in an unusual situation in this outbreak. We have a disease with a high fatality rate without any proven treatment or vaccine,” Dr. Marie-Paule Kieny, WHO’s Assistant Director- General, said in a statement.
"We need to ask the medical ethicists to give us guidance on what the responsible thing to do is.”
ZMapp is one of several experimental Ebola treatments, but there is no approved vaccine or cure for the deadly virus.
Given that even unproven treatments are in short supply, the WHO panel will also discuss who should receive them.
The first human clinical trial of an
Ebola vaccine is set to begin
sometime in September, said Dr.
Anthony Fauci, director of the
National Institute of Allergy and
Infectious Diseases at the National
Institutes of Health. If successful, it
will likely take until mid- or late-2015 before a limited number of health care workers can receive the vaccine,
he said.